Kiora director granted 25,000 stock options

Kiora Pharmaceuticals director Lisa Walters-Hoffert received a grant of stock options as part of her compensation.

Rhea-AI Filing Summary

Kiora Pharmaceuticals director Lisa Walters-Hoffert received a grant of stock options as part of her compensation. She was awarded 25,000 options to buy Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.

The options were granted at no cost and relate to 25,000 underlying shares of common stock. They will become fully exercisable on June 10, 2027 and will expire on June 10, 2036 if not exercised. After this grant, she holds 25,000 options directly, and the filing reports no open-market purchases or sales.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider Walters-Hoffert Lisa

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

1. F1. The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.

Key Figures

Option grant size: 25,000 options Exercise price: $2.63 per share Underlying shares: 25,000 shares +3 more

6 metrics

Option grant size 25,000 options Grant to director on June 10, 2026

Exercise price $2.63 per share Strike price for granted options

Underlying shares 25,000 shares Common stock underlying the options

Vesting date June 10, 2027 Date options become fully exercisable

Expiration date June 10, 2036 Option term under 2024 Equity Incentive Plan

Options held after grant 25,000 options Total derivative holdings following transaction

Key Terms

Stock Option, Equity Incentive Plan, exercise price, Common Stock

4 terms

Stock Option financial

"The reporting person received an Option to purchase Common Stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Equity Incentive Plan financial

"pursuant to the Issuer's 2024 Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

exercise price financial

"conversion_or_exercise_price": "2.6300""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common Stock financial

"Option to purchase Common Stock from the Issuer"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Kiora Pharmaceuticals (KPRX) disclose in this Form 4 filing?

Kiora Pharmaceuticals reported a stock option grant to director Lisa Walters-Hoffert. She received 25,000 options under the 2024 Equity Incentive Plan, giving her the right to buy common shares at a fixed $2.63 exercise price if she chooses to exercise later.

How many KPRX stock options were granted to director Lisa Walters-Hoffert?

Lisa Walters-Hoffert was granted 25,000 stock options to purchase Kiora common stock. Each option corresponds to one share, providing potential future ownership of 25,000 shares if exercised according to the plan’s terms and timing requirements.

What is the exercise price of the new Kiora Pharmaceuticals (KPRX) stock options?

The exercise price is $2.63 per share for the 25,000 options granted to Lisa Walters-Hoffert. This price is the fixed cost per share she must pay if she decides to exercise the options within the specified exercise period.

When do the KPRX options granted to Lisa Walters-Hoffert become exercisable?

The options become fully exercisable on June 10, 2027. Before that date, she cannot exercise them. Once vested, she may choose to buy common shares at the $2.63 exercise price any time before the option expiration date.

When do the newly granted Kiora Pharmaceuticals (KPRX) options expire?

The options expire on June 10, 2036 if they are not exercised. After that expiration date, Walters-Hoffert would lose the right to purchase Kiora common shares under this specific 25,000-option grant.

Does this Kiora Pharmaceuticals Form 4 show any open-market buying or selling of KPRX shares?

No, this Form 4 reflects a compensation-related option grant rather than an open-market trade. The reported transaction is a grant of 25,000 stock options, not a purchase or sale of existing KPRX common shares on the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walters-Hoffert Lisa

(Last) (First) (Middle)

C/O KIORA PHARMACEUTICALS, INC.

169 SAXONY RD., SUITE 212

(Street)

ENCINITAS CALIFORNIA 92024

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KIORA PHARMACEUTICALS INC [ KPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.63	06/10/2026		A		25,000		06/10/2027(1)	06/10/2036	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. The reporting person received an Option to purchase Common Stock from the Issuer pursuant to the Issuer's 2024 Equity Incentive Plan. The Option will become fully exercisable on June 10, 2027.

Remarks:

	/s/ Melissa Tosca, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)